PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. Electronic address: quirin.hammer@ki.se.\', \'Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.\', \'Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.\', \'Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.\', \'Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.\', \'Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.\', \'Institute for Systems Analysis and Computer Science \'A. Ruberti,\' National Research Council (IASI-CNR), Rome, Italy.\', \'Innate Immunity, Deutsches Rheuma-Forschungszentrum (DRFZ), Institute of the Leibniz Association, Berlin, Germany.\', \'Innate Immunity, Deutsches Rheuma-Forschungszentrum (DRFZ), Institute of the Leibniz Association, Berlin, Germany; Division of Gastroenterology, Infectiology and Rheumatology, Medical Department I, Charité-Universitätsmedizin Berlin, Berlin, Germany.\', \'Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.\', \'Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2211-1247(22)00239-X10.1016/j.celrep.2022.110503
?:doi
?:hasPublicationType
?:journal
  • Cell reports
is ?:pmid of
?:pmid
?:pmid
  • 35235832
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.552
?:rankingScore_hIndex
  • 92
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35235832>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35235832>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all